New Therapeutics from Thüringen: A Gera-based biotech company is producing new compounds for clinical studies
The Thuringia Start-up Fund (TSF), which is managed by bm|t, has invested in BianoGMP for the production of DNA and RNA based therapeutics.
There remain many prevalent diseases without effective treatments. Thankfully, there is an abundance of small companies and research groups working on new compounds to address these diseases. In recent years there has been a research movement toward DNA and RNA based therapeutics. However, before these innovative compounds can be tested with patients in clinical studies the quality of the production must be assured using GMP, or Good Manufacturing Practice, in industry parlance.
“BianoGMP will act as an innovative small and mid-size batch producer for the companies and researchers that are developing these DNA and RNA based compounds, making the path to the clinic less arduous,” stated Stefan Jahn, Investment Manager at bm|t.
The BianoGMP team has been working for many years with RNA therapeutics and developed a new class of patented compounds as part of a grant-funded project with Friedrich-Schiller University in Jena. “Our partner company, BianoScience GmbH will be one of the first customers and beneficiaries of BianoGMP´s production services. Patients will also benefit from our services in that innovative therapeutics will have a quicker development path,” said Dr. Tobias Pöhlmann, CEO from BianoGMP.
Dr. Rolf Günther, Co-CEO from BianoGMP focused on the role of regional investors: “This investment from bm|t, the MBG, and many private individuals from Thuringia will allow us to build a highly-challenging and high-performance production facility in Gera. We will work with therapeutic developers to make their development work more efficient and the path to the clinic faster.”
About bm‑t
Erfurt-based, beteiligungsmanagement Thüringen (bm|t) – a subsidiary of the Thuringia Development Bank, is the first address for investments in Thuringia, Germany. bm‑t currently manages eight investment funds with a total volume of 320M EUR. bm‑t invests in innovative companies with strong growth potential across all sectors and all phases of the corporate lifecycle.
About MBG
The MBG mbH has been established in Thuringia for 25 years. With over 100 investments in its portfolio, the MBG is a major supporter of company formation, established enterprises, and succession planning in Thuringia.
About Biano GMP
BianoGMP was founded in August 2017 with the aim of being a GMP service provider for small to medium batch sizes in the field of oligonucleotides. By offering outsourced small and medium sized batch production, BianoGMP will allow early-stage biotech companies to reduce costs and shorten their development timelines. The company is also developing methods to offer a wide-range of oligo development and production capabilities.
Press Contacts
BianoGMP GmbH
Dr. Tobias Pöhlmann und Dr. Rolf Günther
Ronneburger Straße 74
07546 Gera
Tel: +49 365 77347180
Email:
www.BianoGMP.com
bm‑t beteiligungsmanagement thüringen gmbh
Stefan Jahn und Katrin Uschmann
Gorkistraße 9
99084 Erfurt
Tel: +49 361 7447 601
Fax: +49 361 7447 635